Riskpilot← Back to searchSign inGet full accessMylan AB
ABActiveOrg 5562790344Pipers Väg 2 AWholesale of pharmaceutical and medical goods · NACE 4646Est. 198650-99 employees
Revenue 2024
SEK 1,7B
+10% vs 2023
EBITDA margin
5.0%
-48% vs 2023
Equity ratio
3.1%
Financial strength
Net profit 2024
SEK -35,9M
-266% vs 2023
| Revenue | SEK 1,7B | +10% |
| EBITDA | SEK 82,2M | -48% |
| Net profit | SEK -35,9M | -266% |
| Total assets | SEK 1,1B | -33% |
| Equity | SEK 35,1M | -51% |
| Employees | — | — |
Legal name
Mylan AB
Org number
5562790344
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
10 juni 1986
Share capital
SEK 1 000 000
Employees
50-99
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall driva fabriksrörelse och handel främst inom läke- medelsbranschen samt därmed förenlig verksamhet.
Address
Pipers Väg 2 A
Phone
+46855522750
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 362 935 | 389 474 | 374 391 | 502 709 | 603 808 | 1 426 616 | 1 501 379 | 1 653 933 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −12 501 | −40 360 | −15 796 | −8 034 | −5 110 | 79 168 | 55 791 | 227 914 | 157 995 | 82 229 |
| Depreciation & amort. | −179 | −196 | −170 | −212 | −199 | −139 | −291 | −150 374 | −686 | −677 |
| EBIT | −12 680 | −40 556 | −15 966 | −8 246 | −5 309 | 79 029 | 55 500 | 77 540 | 157 309 | 81 552 |
| Net financials | −425 | −248 | −1 349 | −4 000 | −458 | −5 844 | −5 379 | −6 700 | −46 231 | −84 479 |
| Profit before tax | −13 104 | −40 804 | −17 314 | −8 660 | −5 767 | 5 841 | 54 018 | −3 491 | 27 622 | −31 787 |
| Tax | −0 | −0 | 16 562 | 727 | 858 | −1 701 | −11 173 | 551 | −5 937 | −4 107 |
| Net profit | −13 104 | −40 804 | −752 | −7 933 | −4 909 | 4 140 | 42 845 | −2 940 | 21 685 | −35 894 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 139 977 | 202 595 | 257 116 | 278 328 | 267 240 | 235 563 | 1 245 827 | 1 341 394 | 1 659 450 | 1 118 161 |
| Equity | 8 193 | 8 842 | 8 089 | 10 156 | 5 247 | 9 386 | 52 231 | 49 291 | 70 976 | 35 082 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 2 622 | 25 882 | 36 598 | 44 325 | 50 882 |
| Short-term debt | 131 784 | 193 753 | 249 026 | 268 172 | 261 993 | 223 555 | 1 167 714 | 1 255 505 | 1 535 023 | 1 023 072 |
| Total debt | 131 784 | 193 753 | 249 026 | 268 172 | 261 993 | 226 177 | 1 193 596 | 1 292 103 | 1 579 348 | 1 073 954 |
EBITDA margin
5.0%
This company
15.8%
Market median
-68% vs market
20152024
Equity ratio
3.1%
This company
38.2%
Market median
-92% vs market
20152024
Return on equity
-102.3%
This company
18.4%
Market median
-656% vs market
20152024
Net profit margin
-2.2%
This company
8.1%
Market median
-127% vs market
20152024
Asset turnover
1.48×
This company
1.12×
Market median
+32% vs market
20152024
Debt / equity
30.87×
This company
0.62×
Market median
-4879% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AP Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2021 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Scandinavian Pharmaceuticals-Generics Aktiebolag | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bgp Products ABMeda AktiebolagScandinavian Pharmaceuticals-Generics Aktiebolag
Mylan AB (this company)Board members of Mylan AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Arne Pontus Pålsson | Chief Auditor | 0 companies |
| Lars Henrik Andreas Rejnus | Chairman | 0 companies |
| Alexandra Ceri Zens | Board of Directors | 0 companies |
| Jenny Friberg | Board of Directors | 0 companies |
| Jan-Christer Stefan Engryd | Board of Directors | 0 companies |
| Jose Javier Cotarelo | Board of Directors | 0 companies |
| Arun Narayan | Board of Directors | 0 companies |
| Vidar Sie | Chairman | 0 companies |